Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Dimerix Limited ( (AU:DXB) ) has shared an update.
Dimerix Limited has announced the issuance of 212,170 fully paid ordinary shares following the cashless exercise of 799,500 unlisted options. This move, which was made without disclosure under Part 6D.2 of the Corporations Act 2001, signifies the company’s adherence to regulatory compliance and may impact its market positioning by potentially increasing liquidity and shareholder value.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.46 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited is a company operating in the biotechnology sector, focusing on the development of innovative therapies for unmet medical needs.
Average Trading Volume: 1,497,148
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$309.1M
For detailed information about DXB stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “Losing the Console Race by Miles”: Microsoft Stock (NASDAQ:MSFT) Ticks Up as the Console Wars Gain a Bit of Clarity
- “…In 18 Months This is a $35,000 Truck” Tesla Stock (NASDAQ:TSLA) Surges With New Pricing Projections
- “Historic Union Busting”: Starbucks Stock (NASDAQ:SBUX) Slips as Strikes Gain Ground, Draw Congress Reps